Workshop
IPTA-SPLIT: Cardiac liver disease

|
Room: MOA 5
Track: N/A

Description

- Discuss the definition of congestive hepatopathy and cardiac liver disease as whole – including long-term complications and the importance of monitoring
- Review the benefits of liver biopsy in the management of congestive hepatopathy and its impact on the transplant discussion.
- Examine the risk associated with liver biopsy in this patient population and alternative ways to monitor complications of congestive hepatopathy – including the mixed review of liver biopsy pathology benefit

Presentations

Dr. Chaowapong Jarasvaraparn, United States
Congestive hepatopathy: Risks, surveillance and management

Dr. Alyssa Kriegermeier, United States
Liver biopsy is key: The importance of a liver biopsy for disease management and long-term predictions

Elizabeth Rand, United States
Liver biopsy is too risky without reward: Alternative ways to monitor congestive hepatopathy and why liver biopsy is not needed

Dr. Alyssa Kriegermeier, United States
Pro liver biopsy response

Elizabeth Rand, United States
Con liver biopsy response

Discussion Period, Germany
Questions from Audience

Email: info@ipta2025.org
514-874-1717